



Contact: Jennifer Cook Williams  
Investor Relations  
ImmunoCellular Therapeutics, Ltd.  
(360) 668-3701  
ir@imuc.com

## **ImmunoCellular Therapeutics To Present at the Biotech/Pharma/Healthcare Informed Investors Forum**

**LOS ANGELES, CA – May 13, 2008** – ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB ) (IMUC) today announced that Manish Singh, Ph.D., president and chief executive officer, and John Yu, M.D., chairman of the board, scientific founder and chief scientific officer, will present at the Biotech/Pharma/Healthcare Informed Investors Forum. The presentation will be webcast on May 15, 2008 at 10:30 a.m. EDT. Drs. Singh and Yu expect to provide updates on the company's activities including its clinical-stage cancer vaccine program for brain cancer.

To access the live webcast or the subsequent archived recording, log on to [www.investorcalendar.com](http://www.investorcalendar.com). Please connect to the website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

### About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based development stage company that is developing immune based therapies for the treatment of brain and other cancers. IMUC's lead product candidate-a dendritic cell-based vaccine for treating brain tumors-is currently being evaluated in a Phase I clinical trial. Additionally, the company is developing a therapeutic vaccine targeting cancer stem cells for multiple cancer indications and will also begin evaluating its newly acquired monoclonal antibody-related technology for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit [www.imuc.com](http://www.imuc.com).

###